Evidence map›Paper›PMID 41920260›Full record

ArticleChinese journal of integrative medicine2026

Shenling Baizhu Powder Alleviated Lung Damage and Enhanced Immunoregulatory Activity in Mice with Non-Tuberculosis Mycobacterial Lung Disease.

Li-Bo Zhen, Hui-Jie Wang, Ting Mo, Xiao-Qing Ma, Yang-Min Jia, Ju-Wei Gao

Abstract read
PubMed Publisher
In one paragraph

Article in Chinese journal of integrative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Li-Bo ZhenDepartment of Tuberculosis, Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine, Hangzhou Red Cross Hospital, Hangzhou, 310006, China. zhenlibodoctor@zcmu.edu.cn.
Hui-Jie WangDepartment of Tuberculosis, Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine, Hangzhou Red Cross Hospital, Hangzhou, 310006, China.
Ting MoDepartment of Tuberculosis, Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine, Hangzhou Red Cross Hospital, Hangzhou, 310006, China.
Xiao-Qing MaDepartment of Tuberculosis, Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine, Hangzhou Red Cross Hospital, Hangzhou, 310006, China.
Yang-Min JiaDepartment of Occupational Medicine, Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine, Hangzhou Red Cross Hospital, Hangzhou, 310006, China.
Ju-Wei GaoDepartment of Oncology, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310006, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the effects of Shenling Baizhu Powder (SLBZP) on non-tuberculous mycobacteria (NTM)-induced lung disease in mice.

methodsAn NTM lung disease mouse model was established by Mycobacterium kansasii infection. C57BL/6J female mice were randomly divided into 5 groups by a random number table (n=6): negative control, NTM, SLBZP-L (2.34 g/kg), SLBZP-H (4.68 g/kg), and rifampicin (20 mg/kg). M. kansasii load in the lungs, liver, and spleen was quantified. Lung histology was performed using hematoxylin and eosin staining. Gene and cytokine expressions related to CD4

resultsSLBZP-L and SLBZP-H treatments inhibited M. kansasii growth and reduced the histological damage and granuloma lesion areas in lungs of mice (P<0.01). SLBZP-H increased interleukin (IL)-17A and interferon-gamma (IFN-γ) levels, along with the proportion of CD4

conclusionSLBZP alleviated NTM-induced lung damage and enhanced NK cell immune response, which might be linked to CD4

Indexed as

Drugs, Chinese HerbalLungLung DiseasesMycobacterium Infections, NontuberculousAnimalsCD4-Positive T-LymphocytesCytokinesFemaleKiller Cells, NaturalMiceMice, Inbred C57BLMycobacterium kansasiiPowdersBaizhuCytokinesDrugs, Chinese HerbalPowdersCD4+ T cellChinese medicineMycobacterium kansasiinatural killer cellnon-tuberculosis mycobacteriumShenling Baizhu Powder

Identifiers

PMID41920260

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.